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Summary
Brown adipocytes regulate energy expenditure via mitochondrial uncoupling. This
makes these fat cells attractive therapeutic targets to tackle the burgeoning issue of
obesity, which itself is coupled to insulin resistance, type 2 diabetes, cardiovascular
and fatty liver disease. Recent research has revealed a complex network underlying
brown fat cell differentiation and thermogenic activation, involving secreted
factors, signal transduction, metabolic pathways and gene regulatory components.
Given that brown fat is now reported to be present in adult humans, it is desirable
to harness the knowledge from each network module to design effective therapeutic
strategies. In this review, we will present a systems perspective on brown adipogen-
esis and the subsequent metabolic activation of brown adipocytes by integrating
signaling, metabolic and gene regulatory modules with a specific focus on known
‘druggable’ targets within each module.
Keywords: Brown adipogenesis, gene regulatory network, metabolism, signal
transduction.
Introduction
With the increase in the global incidence of obesity and
its associated pathologies, collectively termed the meta-
bolic syndrome, there is renewed interest in exploring
pathways that modulate energy balance in mammalian
systems (1). Disproportional energy intake over expendi-
ture leads to energy imbalance, excessive fat storage in
the white adipose tissue (WAT), and disturbance of whole
body homeostasis, igniting intense investigation into path-
ways that would enhance energy homeostasis (2,3). The
latter is in part mediated by fat depots via secretion of
cytokines and interaction with various organs of the
body. WAT, known as an endocrine-type storage organ,
is capable of secreting adipokines such as leptin and
adiponectin (4), and communicating with different organs
such as the brain, muscle and liver to regulate energy
homeostasis as well as the immune response. Excessive
energy intake leads to WAT hyperplasia (increase in the
number of mature adipocytes) and/or hypertrophy
(adipose tissue expansion). Given its status as an energy
reservoir, WAT has therefore been the primary target to
combat obesity. However, results have been discouraging
due to lipid divergence, leading to the accumulation
of lipids in other organs such as skeletal muscle, kidney
and liver, ultimately causing the development of meta-
bolic disorders. For instance, in response to the
adipocyte-specific deletion of peroxisome proliferator-
activated receptor gamma (Pparg), severe lipoatrophy is
observed in mice, but the mass of Pparg null mice and
their wild type littermates is similar, with the Pparg null
mice demonstrating lipid divergence and afflictions such
as fatty liver, diabetes and severe insulin resistance (5).
This underscores the importance of designing effective
therapies that lack adverse systemic side effects. While
dietary restriction and exercise have a positive impact
on adipose mass leading to diminished fat storage (6),
novel strategies to improve whole body homeostasis
and restore metabolic balance are being explored to
aid metabolically challenged patients. With the recent
positron emission tomography – computed tomography-
based (PET-CT) discovery of metabolically active brown
fat and recruitable brown-in-white fat depots in adult
humans (7), current work in the field has turned to
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explore ways to maximize energy expenditure via the
brown adipose tissue (BAT) to combat excessive fat accu-
mulation and restore energy homeostasis.
The presence of a second type of adipose tissue, BAT,
has been originally described both in rodent models and
in human infants, (8), as the thermogenic activity of
BAT is essential for the endurance of small mammals in
cold environments. A brown adipocyte is characterized
by densely packed, iron-rich mitochondria, rendering it
brown in color, and is capable of converting free fatty
acids into heat via the action of the uncoupling protein
1 (UCP1) in response to various stimuli, most notably
cold and diet (8). Apart from classical brown fat, WAT
also harbors pockets of UCP1-expressing cells with ther-
mogenic capacities that arise in response to various stimuli
(9). These adipocytes are known as beige or brite (brown-
in-white) or recruitable BAT (10) and display similar
features to BAT, such as high mitochondrial content,
multilocular lipid droplets and expression of a key set of
brown fat marker genes (Ucp1, Cidea, Pgc1a) despite
originating from different cellular lineages (11). Classical
brown fat cells develop from pluripotent precursor cells
in the somites that express transcription factors (TFs) such
as PAX7, Homeobox protein engrailed-1 (EN1) and
Myogenic factor 5 (MYF5). These TFs later determine
the development of these precursor cells either into brown
fat cells, skeletal myocytes, dorsal dermis or a subset of
white adipocytes (12). On the other hand, lineage-tracing
analysis showed that beige fat cells, together with another
subset of white adipocytes, originate from Myf5-negative
populations of progenitors (13) and express characteristic
genes such as those coding for cluster of differentiation-
137 (Cd137), T-box 1 (Tbx1) and transmembrane protein
26 (Tmem26) (14). Interestingly, a significant portion of
the brown fat from adult humans that is present in the
neck and supraclavicular regions has the molecular
characteristics of beige (or recruitable) BAT rather than
classical BAT (14,15). This is unlike the interscapular
depots of human infants that have been shown to resem-
ble classical BAT found in rodents using high resolution
imaging, as well as histological and biochemical analyses
(16). To design effective therapies promoting BAT activity
in metabolically challenged human subjects, it is impor-
tant to have a thorough understanding of the molecular
mechanisms underlying brown fat cell development and
activity. This review is an attempt to integrate the signal-
ing, metabolic and transcriptional modules governing
brown fat differentiation and metabolic activation with
an additional focus on the white to brown axis. We envi-
sion that this network-based perspective will contribute to
the identification of unexplored pathways or incomplete
mechanistic details regarding key regulators and signaling
molecules, aiding in the development of targeted therapeu-
tic approaches.
Part 1: Metabolic activity of brown adipose tissue
Uncoupling protein 1, the core player in brown adipose
tissue activation
The process of ‘uncoupling’ substrate oxidation from aden-
osine triphosphate (ATP) synthesis, i.e. thermogenesis,
occurs in brown adipocytes and is catalyzed by the mito-
chondrial protein UCP1 (8). UCP1 is a multi-pass mitochon-
drion inner membrane protein and member of the
mitochondrial carrier protein family (SLC25) (17–20).
Ucp1 null mice show little resistance to cold and are not ca-
pable of sustaining their body temperature during prolonged
cold exposure, suggesting a crucial role for UCP1 in cold-
induced thermogenesis (21). Thermogenesis at the molecular
level begins when free long chain fatty acids (LCFAs) liber-
ated from the abundant multilocular fat droplets within the
brown adipocyte are activated by acyl-CoA synthase to acyl
CoAs and transferred into the mitochondria. This results in
beta-oxidation of LCFAs (now acyl-CoAs), which, in combi-
nation with the Krebs cycle, produces the reduced electron
carriers, Flavin adenine dinucleotide (FADH2) and Nicotin-
amide adenine dinucleotide (NADH). The latter are subse-
quently oxidized within the respiratory chain, which causes
the protons to be pumped out of the mitochondria, ulti-
mately resulting in the formation of a proton-motive force.
UCP1 then mediates the influx of protons back into the mi-
tochondrial matrix without ATP being synthesized. Rather,
the energy stored in the proton-motive force is liberated as
heat (8,22). More specifically, the mechanism by which
UCP1 transports H+ ions has recently been elucidated using
the patch clamp technique. The latter allowed direct mea-
surement of UCP1 currents in the native inner membrane
of BAT mitochondria, demonstrating that UCP1 is a
symporter of LCFAs/H+. Thus, LCFAs serve as primary sub-
strates that associate with UCP1 via hydrophobic interac-
tions and enable UCP1 to transport H+ ions, thereby
mediating thermogenesis (23).
Part 2: Known therapeutic interventions in humans
Non-drug-based approach
Methods that are employed to induce BAT development and
activation, aiming to improve whole body energy homeosta-
sis, include the following:
Cold exposure
Cold exposure, to our knowledge, is the most efficient
approach to induce BAT development and activation
(24,25), and it does so via the sympathetic nervous system
(SNS) as well as the norepinephrine (NE)-dependent signal
transduction pathway (Fig. 1). Numerous studies showed that
the effects of chronic cold exposure are compelling and signifi-
cantly improve systemicmetabolic homeostasis, including insu-
lin sensitivity as well as glucose and lipid profiles (24–27).
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Nevertheless, results of adult human-based studies revealed im-
portant discrepancies, perhaps due to varying study conditions
and experimental designs (10). This illuminates the need for
standardized experimental protocols to better assess and com-
pare the actual impact of cold exposure on human BATactivity
across individuals and studies.
Figure 1 Schematic representation of factors that promote development and activity of brown and beige adipocytes. Shown are factors with therapeutic
potential as BAT potentiators. Physiological stimuli originating at the systemic level can be divided into 1) cold exposure-derived factors namely norepi-
nephrine (NE) that is secreted by the SNS; 2) exercise-induced myokines including irisin, Meteorin-like (METRNL), interleukin 6 (IL-6), lactate and β-
aminoisobutyric acid (BAIBA); and 3) insulin as a post-prandially secreted factor. In addition, endocrine stimuli are also visualized including thyroid hor-
mone T3, natriuretic peptides (NP), fibroblast growth factor 21 (FGF21), bone morphogenetic protein 7 (BMP7), bone morphogenetic protein 8b (BMP8b),
orexin (OX), vascular endothelial growth factor (VEGF) and prostaglandins (PG). Finally, several synthetic molecules are also shown that can act as BAT
inducers but that are no longer used given their adverse secondary effects: mitochondrial uncoupler: 2,4-dinitrophenol, β3-adrenoreceptor agonist: CL
316,243 and PPARγ activators: thiazolidinediones (TZDs). The presented list of factors activating BAT is not exhaustive. A few organ schemes originate
from Servier Medical Art. Figure legend: Organs from top (clockwise): Brain,Skeletal muscle, WAT, Heart, Liver, Thyroid, BAT and Pancreas.
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Exercise
The role of exercise in enhancing and maintaining overall
fitness, health and well-being is incontestable. It is an
established physiological method for improving muscle
strength and cardiovascular system condition, decreasing
body weight and allowing its maintenance, protecting
against type 2 diabetes, as well as awarding enjoyment
through endorphin production (28,29). In light of recent in-
terest in BAT physiology, the cocktail of metabolic factors
that is secreted during exercise was analysed in various stud-
ies in the context of BAT development and activation (12).
This led to the identification of a number of molecules such
as Irisin, Meteorin-like, IL-6, lactate, beta-aminoisobutyric
acid amongst others (30–35) (Fig. 1). However, as with
chronic cold exposure, it remains to be established how
much of the beneficial effect of exercise occurs via BAT
activation.
Bioactive food ingredients
Another non-drug-based factor discussed in the context of
BAT activity enhancement is diet, which along with exercise
has a powerful beneficial impact on overall health and
fitness. Alternative dietary options, including substances
such as green tea, ginger, capsaicin (36) amongst others,
have been reported to induce BAT activity. Green tea, for
instance, contains caffeine and remarkable quantities of
catechin-polyphenols (notably epigallocathechin gallate).
These molecules interact to induce 24 h energy expenditure
and fat oxidation, thereby implicating them as effective
activators of sympathetically mediated thermogenesis (37).
Similarly, ginger, with its bioactive constituents gingerols
and shogaols (38), was shown to enhance the thermic effect
of food (39). Although it was reported that ginger-
supplemented high-fat diet fed rats presented lower
insulin, glucose and lipids versus the control rats (38), no
such effect was observed in an equivalent study conducted
in humans (39).
Drug-based approach
The abundance of brown fat and its activation by cold vary
according to the extent of obesity of human subjects
(7,24,26,40). Studies that directly measure oxidative
metabolism in BAT by 15O PET blood flow demonstrated
that the level of cold-inducible thermogenesis in most
individuals is less than 10 kcal/day (41)–(42). In contrast
to cold adapted rats where the blood flow to BAT can reach
up to 1,000 ml/min/100 g (43,44), in acute cold-stressed,
but chronically warm-adapted humans, the rate is
15–20 ml/min/100 g (41,42,45). To achieve a similar effect,
for instance, via exercise, the thermogenic activation of
BAT in humans needs to be increased 40–50-fold (46).
Hence, drug-based therapies have been proposed to
enhance the activity of BAT in metabolically challenged
individuals where diet and exercise regimen alone is not
sufficient to promote the metabolic activity of BAT. These
include chemical uncouplers such as dinitrophenol, which
was used extensively but is associated with complications
such as hyperthermia and has since been banned. Alterna-
tively, several groups demonstrated the effect of UCP1-
specific activators and other futile cycles that may provide
metabolic benefit within a tolerable safety profile. This is ev-
idenced by the directed release of mitochondrial
protonophores that can improve insulin resistance, diabetes,
hypertriglyceridaemia and hepatic steatosis by safely
uncoupling in the liver of rats (47). Other drugs include
beta-3 selective adrenergic agonist CL-316,243 that can
potently activate brown and beige fat in rodents and is
known to improve insulin action in human clinical trials
(48). Currently, acute dosage of Mirabegron, a drug that
has been used to treat an overactive urinary bladder, has
been shown to activate brown fat. Mirabegron is therefore
a candidate in consideration for a putative drug under the
condition that its effect is constant upon chronic dosing
and without adverse cardiovascular side effects (49).
Thiazolidinediones (TZDs), well-known PPARg agonists,
are known to cause browning of white fat by stabilizing
PR domain containing 16 (PRDM16), a transcriptional
co-regulator of the early brown fat differentiation program.
However, they also have a rather negative impact such as
weight gain, fluid retention and cardiovascular events,
reducing interest in their use. Additional molecules of inter-
est include bone morphogenetic proteins such as BMP7 and
BMP8b, cyclooxygenase-2 (COX2) and natriuretic pep-
tides, and fibroblast growth factor 21 (FGF-21). However,
these molecules have pleiotropic effects, underscoring the
importance of delineating signaling and transcriptional
pathways both upstream and downstream of the targeted
factor. The following sections will therefore focus on key
signaling and gene regulatory modules and mechanisms as
well as highlight putative ‘druggable’ targets.
Part 3: Secreted factors for brown adipose tissue
recruitment
Numerous factors were demonstrated to positively recruit
BAT (or beige adipose tissue) activity via endocrine, para-
crine or autocrine mechanisms (10,50). These include (i)
natriuretic peptides that bind to natriuretic receptors on
brown or beige adipocytes, and that trigger lipolysis and
thermogenesis by activating cyclic GMP-dependent pro-
tein kinase (PKG) (10,51); (ii) irisin, a newly identified
hormone that is induced in mouse and human muscle
by exercise and that stimulates UCP1 expression (10,30);
and (iii) orexin, a neuropeptide that triggers the brown
fat cell differentiation program by impacting the sympa-
thetic outflow via p38 MAPK as well as the bone mor-
phogenetic protein receptor 1-A-dependent Smad1/5
signaling (10,52) and FGF family members including
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FGF-21 and FGF-15/19 that mediate browning and
glucose homeostasis (53).
Part 4: Signal transduction pathways
Although lipid-storing cells evolved late during the course of
evolution, it has been observed that evolutionarily ancient
factors and pathways are highly active during adipogenesis
and have either an activatory or inhibitory effect on adipo-
cyte development. Some pathways are also known to
exhibit dichotomic effects and are poorly characterized in
the context of adipogenesis, particularly regarding how they
converge on key transcriptional programs (54). As these
signaling pathways control tightly regulated transcriptional
cascades, further investigation into the transmission of sig-
nals is valuable. The core adipogenic circuit comprises the
master regulator PPARg along with CCAAT/enhancer bind-
ing protein alpha (C/EBPa), and many signaling events are
focused on the activation of this regulatory circuit. On the
other hand, initiation of brown fat cell differentiation and
activation of the thermogenic circuit require additional tran-
scriptional regulators and co-regulators such as PRDM16,
peroxisome proliferator-activated receptor gamma coacti-
vator 1 alpha (PGC1a) that are also stimulated by specific
signal transduction pathways. In this part, we highlight
and summarize important signaling events that impact
brown adipogenesis and identify key ‘drug-able’ targets
where possible. A comprehensive overview of key signaling
pathways and gene regulatory networks is presented in
Fig. 2, highlighting the complexity of the network.
Beta-adrenergic signaling
Beta-adrenergic receptor signaling functions via three
types of adrenergic receptors: b, a2 and a1 that respond
to the catecholamine, NE which is released as a
consequence of cold-induced or leptin-mediated activation
of the SNS. The activation of beta-adrenergic receptor sig-
naling further promotes the activation of different signal-
ing pathways in brown adipocytes. Of the three subtypes
of beta-adrenergic receptors, beta 3 adrenergic receptor
(ADRB3) is predominantly found in mature brown adipo-
cytes, while beta 1 adrenergic receptor (ADRB1) is found
in brown pre-adipocytes. Beta-adrenergic receptors are
known to couple to G proteins of the Gs subtype and
execute the thermogenic signaling cascade via adenylyl
cyclase activation. It has been demonstrated that ADRB-1
and -3 mediated thermogenic activation and upregulation
of oxidative metabolism are highly effective in elevating
whole-body thermogenesis in both rodents (44,55) and
humans (56).
Thyroid signaling
Thyroid hormones bind to thyroid hormone receptors (TR)
a1–2 and b1–2 to execute pleiotropic effects such as growth
and metabolism in several target tissues throughout the
body, such as liver, bone, fat and heart. Particularly in
brown fat, Thyroxine or T4 is converted to its metabolically
active form, Triiodothyronine or T3, by type 2 deiodinase
(DIO2) following sympathetic stimulation (57). T3 further
acts in concert with norepinephrine to stimulate Ucp1 gene
expression in the BAT in rats (58,59). To determine the TR
isoforms regulated by T3, pharmacological and genetic
screening approaches have been used, leading to the identi-
fication of TRb-1 agonist Gc-1, capable of stimulatingUcp1
expression but not affecting the regulation of whole body
temperature. Further, genetic mouse models showed that
TRa activation is important for thermogenesis while TRb
is necessary for cholesterol metabolism (60). Thus, drug
designs targeting thyroid receptors must take this into
account.
Gq signaling
G protein-coupled receptors (GPCRs) are a family of seven
transmembrane proteins that regulate biological processes
in different tissues such as the adipose tissue, via the action
of heterotrimeric G proteins composed of three subunits:
alpha (a), beta (b) and gamma (g). Upon activation of
GPCRs, Ga dissociates from the Gbg dimer causing the
activation of downstream signaling events determined by
G protein coupling. Of the four classes of Ga proteins, Gq
protein is known to activate multiple intracellular signaling
pathways such as ERK, IP3/DAG and RHO/ROCK (61,62).
A GPCR profiling-based approach revealed Gq-coupled
GPCRs to be one of the highly expressed groups of signaling
molecules in murine brown adipocytes that inhibit adipo-
cyte differentiation through the RHO/ROCK signaling cas-
cade. This phenotypic effect was manifested via the
Endothelin-1/Endothelin receptor type A (ET-1/EDNRa)
signaling axis. Further, overexpression of Gq in vivo
induced a phenotype similar to the effect of ‘whitening’ in
BAT, preventing ‘browning’ of WAT in cold-exposed mice
(63–65). Given that approximately 25% of the drugs
available in the market target GPCRs, it seems feasible to
target receptors coupled to Gq to enhance browning in
white fat depots (66).
Wnt signaling
Cell fate and development processes are influenced by the
para- and autocrine activity of the Wnt family of secreted
glycoproteins. The binding of Wnt proteins to frizzled
receptors triggers beta-catenin-dependent, canonical signal-
ing pathways. Canonical Wnt signaling ligands such as
Wnt10b promote osteogenesis in mesenchymal stem cells
(MSCs) and suppress both white and brown adipogenesis.
It has previously been demonstrated that Wnt10b blocks
brown adipose differentiation and affects the expression of
Ucp1 via repression of Pgc1a in mature brown adipocytes
leading to a switch to white adipocytes. Wnt signaling
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may suppress Pgc1a either directly via a beta-catenin LEF1
complex, or interference with transcriptional activity of
Pgc1a regulators such as ATF-2, CREB, FOXO1 or via the
inhibition of upstream signaling molecules such as protein
kinase A or p38 MAPK (67). Other Wnts such as Wnt6,
Wnt10a are also known to suppress adipogenesis and pro-
mote osteoblastogenesis (68). In contrast, Wnt5b positively
regulates adipogenesis by countering the nuclear transloca-
tion of beta-catenin, thus inhibiting the canonical Wnt sig-
naling pathway (69).
Hedgehog signaling
Hedgehog (HH) ligands bind to the Patched-1 (PTCH1)
receptor and liberate Smoothened (SMO), a downstream
protein in the pathway, from the inhibitory effect of PTCH1
causing SMO to regulate gene transcription of GLI proteins
that negatively regulate adipogenesis (54). Also, it is likely
that SMO indirectly activates the GATA factors that are
known to be anti-adipogenic (70). Extrapolation of results
from a systems level genetic dissection of adipose regulation
inDrosophila melanogaster to the murine system implicated
HH signaling pathway as being inhibitory for white but not
for brown fat formation (71). In contrast, a more recent
study demonstrated that HH signaling operates in a cell-
autonomous manner to block brown adipocyte differentia-
tion, inhibit in vivo BAT formation and replace neck BAT
in rodents into poorly differentiated skeletal muscle, par-
tially via the upregulation of chicken ovalbumin upstream
promoter transcription factor II (Coup-TFII) (72). The
differences between these two studies could be attributed
to the in vivo system used to assess the phenotypic effect
of HH signaling on adipose depots thereby highlighting
the importance of interpreting phenotypic outcomes
obtained from in vivo data (72).
Janus kinase–signal transducers and activators of
transcription signaling
Janus kinases (JAKs) are associated with various cell surface
receptors, whose activity is triggered via ligands such as
interferon, interleukin and growth factors. Activated JAKs
recruit SH2 domain containing proteins (signal transducers
and activators of transcription (STATs)) to the receptors via
phosphorylation and are further tyrosine phosphorylated
by JAKs. These activated STATs then translocate to the
nucleus, form hetero- or homo-dimers and regulate tran-
scription of target genes. Recently, Janus kinase inhibitors
were identified as molecules that possess ‘browning’ poten-
tial, using a screening approach to discover small molecules
capable of promoting a switch from white to brown in
human adipocytes. It was demonstrated that two com-
pounds, tofacitinib and R406, strongly induce UCP1 while
remodeling lipids via the JAK–STAT1/3 pathway, thereby
implicating the IFN–JAK–STAT–SHH axis in human adipo-
cyte biology. Of the two potential drugs identified, the drugFi
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tofacitinib is sanctioned in the United States for rheumatoid
arthritis (73). Additionally, because the JAK–STAT pathway
is involved in immune system regulation, local administra-
tion of the drug or ex vivo transplantation of cells post-
treatment is recommended to limit deregulated immune
activation.
Transforming growth factor-beta signaling
Transforming growth factor beta (TGF-b), myostatin and
bone morphogenetic proteins regulate the differentiation
of many cell types including adipocytes. While subsequent
signaling events have common properties, specific TGF-b
family members influence distinct cell fate decisions by
binding to serine/threonine kinase receptors and functioning
through SMAD-dependent and -independent mechanisms.
Transcriptional regulation of target genes is executed by
receptor-regulated SMAD1 and SMAD3 TFs, which, upon
phosphorylation, engage in dimer formation with SMAD4,
and subsequently translocate to the nucleus. In adipogene-
sis, the canonical TGF-b signaling pathway has an unclear
molecular function. While TGF-b expression correlates pos-
itively with obesity in humans, it inhibits in vitro adipogen-
esis of 3T3-F442A cells by signaling through SMAD3. It has
been observed that supplementing wild-type mice with
exogenous TGF-b1 reduced thermogenic gene expression
in fat (74), implicating TGF-b signaling in the negative reg-
ulation of browning. This has been exploited for therapeutic
purposes as evidenced in a study where a dominant negative
form of activin receptor type II-b fusion protein was used to
promote thermogenesis in mice by binding to TGF-b,
thereby preventing downstream signaling (75).
Bone morphogenetic protein signaling
Bone morphogenetic proteins (BMPs) are categorized as a
family within the TGF-b superfamily with the ability to
stimulate white and brown fat cell differentiation programs.
While BMP2 and BMP4 are known to induce commitment
to the white adipocyte fate when supplemented by a
hormonal induction cocktail, BMP7 is known to singularly
support brown fat cell differentiation in both MSC progen-
itors and committed pre-adipocytes even in the absence of a
differentiation cocktail via the p38 MAPK pathway (76).
p38 MAPK further executes the thermogenesis program
by phosphorylating and activating distinct nuclear receptors
(NRs), ATF2 and PGC1a, which in turn promote Ucp1
expression by binding to a cAMP and PPAR-response
element that resides in a key enhancer of the Ucp1 gene
(77). This phenotypic effect was also observed in vivo,
because Bmp7 null mice show a reduction in brown fat
mass that was rescued upon adenovirus-mediated overex-
pression of Bmp7, thereby protecting the mice from diet-
induced obesity while triggering energy expenditure (76).
BMP7 is also known to function synergistically with
rosiglitazone, a TZD, to give rise to inducible brown
adipocytes from SCA1+ adipocyte progenitor cells that arise
from different fat depots as well as skeletal muscle in mice
(78). Additionally, in vivo studies showed that BMP7
enhances Ucp1 expression in WAT in combination with
the beta3-adrenergic agonist CL-316,243 to levels higher
than those achieved by CL-316,243 treatment alone (78).
This study underscores the importance of the BMP7 signal-
ing pathway in inducing browning and as a viable therapeu-
tic option.
BMP8b is yet another BMP signaling molecule capable of
regulating whole body energy metabolism both centrally,
through AMPK activation in hypothalamic nuclei, and
peripherally, by activating the p38 MAPK signaling path-
way in differentiating and mature brown adipocytes. Using
Bmp8b knockout mice, it was demonstrated that BMP8b
increases the peripheral response of BAT to adrenergic stim-
ulation and acts centrally to increase sympathetic output to
BAT. BMP8b signaling specifically acts on the thermogenic
pathway, as Bmp8b knockout mice do not show gross
abnormality in BAT morphology. Additionally, it has been
proposed that AMPK has a counter-regulatory role, acting
in opposition to BMP8b to regulate energy expenditure,
supported by the observation of greater thermogenic
activation upon localized expression of the dominant nega-
tive AMPK alpha isoform. As AMPK is a known druggable
target in peripheral tissues to treat insulin resistance (79), its
relationship with BMP8b offers new opportunities in
targeted drug design. It is worth noting that the ability of
BMP8b to execute central actions to reduce whole body
weight without compensatory food intake offers an exciting
premise for new therapeutic options, demonstrating the
importance of understanding thermogenesis at a central
regulatory level.
NOTCH signaling
The Delta-like (DLL) and Serrate/Jagged (JAG) family of
membrane bound ligands bind to transmembrane NOTCH
receptors causing gamma-secretase-mediated proteolytic
cleavage of NOTCH, leading to the nuclear translocation
of the NOTCH intracellular domain (NICD). Once in the
nucleus, the NICD activates the RBP-jk transcriptional com-
plex and subsequently its downstream targets such as the
Hes and Hey family genes (80). Constitutive activation of
NOTCH signaling inhibits Pgc1a and Prdm16 transcription
in white adipocytes via HES1-mediated transcriptional
repression and causes ‘whitening’ of BAT. In contrast, inhi-
bition of NOTCH signaling is associated with ‘browning’
of WAT, improvement of insulin sensitivity and whole-body
energy homeostasis (81). This differential response is
intriguing and highlights the involvement of different gene
regulatory programs that are cell-context dependent. As
NOTCH signaling is an evolutionarily conserved pathway,
these findings can be extended to human studies; however,
this merits further investigation into identifying molecular
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mechanisms operating in human white to brown
conversion.
Part 5: Gene regulatory networks
Once adipogenic precursors commit to the adipogenesis
program, a transcriptional circuit is switched on, leading
to the expression of genes associated with fat cells. While
the white and brown differentiation programs share a set
of regulators and adipogenic stimuli, they both have unique
requirements that determine their phenotypic differences. It
is therefore important to delineate both, i.e. the core
adipogenic differentiation and the thermogenic programs,
to get a full picture of the gene regulatory events that give
rise to fully functional brown and brite fat. In this section,
we present an overview of the individual circuits such as
the early and core differentiation, thermogenic and
adipogenic modules within the overall gene regulatory
network. A schematized overview is presented in Fig. 2.
Early differentiation circuit
Early B-cell factors
The early B-cell factors (EBF), especially EBF1 and EBF2,
play an important regulatory function in the early differen-
tiation circuit along with Zinc Finger Protein (ZFP) 423
and its close paralog ZFP521, both implicated as early
regulators of adipose commitment and differentiation
(82,83). ZFP521 functions in a repressive feedback loop
with EBF1, while also repressing ZFP423, thereby influenc-
ing early regulatory events in the lineage switch between
bone and fat (83). ZFP423, on the other hand, functions
by promoting Pparg expression through amplification of
the BMP signaling pathway via SMAD binding (82).
Further, Ebf1 is induced by both CCAAT/enhancer binding
protein delta (C/EBPd) and CCAAT/enhancer binding
protein beta (C/EBPb) and then directly activates both
Pparg (via binding to the Pparg1 promoter) and C/ebpa,
which positively feeds back to C/ebpd (84). A previous
study demonstrated EBF2 to regulate PPARg binding to
determine brown versus white fat fate, leading to its classifi-
cation as a brown-specific transcriptional regulator (85). It
was further suggested that BAT-specific target genes of
PPARg were categorically bound by EBF2 that then served
as a mark for the later recruitment of PPARg at sites regulat-
ing the expression of brown fat selective genes such as
Prdm16 and Ucp1 (85).
PR domain containing 16
The 140 kDa PRD1-BF-1-RIZ1 homologous domain
containing protein-16, PRDM16, is a core transcriptional
co-regulator in both brown and beige fat, showing selective
expression in brown over white fat (13). In vitro cell culture
studies in classical brown fat cells demonstrated the
requirement of PRDM16 to develop and maintain a ther-
mogenic gene program. However, in vivo deletion of
Prdm16 did not affect the function of classical brown fat
but had a significant impact on the development of beige
fat cells. Additionally, deletion of Prdm16 along with its
closest homolog Prdm3 led to an early and extreme loss of
brown fat thermogenic gene expression (86). Most impor-
tantly, PRDM16 has been demonstrated to function as a
molecular switch between white and brown programs by
coupling with diverse protein interaction partners simulta-
neously, mediating both activating and repressive gene
expression programs. These dichotomous activities are exe-
cuted through the use of chromatin remodellers, C-terminal
binding proteins (CtBPs) that function via the recruitment of
histone deacetylases (87). PRDM16 interacts with either
PGC1a or CtBPs to, respectively, activate the brown or sup-
press the white gene expression program. During brown fat
activation, recruitment of PGC1a displaces CtBPs from the
complex to activate brown fat-specific genes. Additionally,
it has been suggested that PRDM16 binds to specific TFs
linked to the promoters/enhancers of target genes, further
guiding the recruitment of PGC1a or CtBPs to initiate the
formation of a co-activator or a co-repressor complex
(87). The TFs that guide PRDM16 to its respective target
genes and their molecular underpinnings have not been
mapped yet, and it is quite likely that numerous factors
are involved in this regulatory process.
Placenta-specific 8
Placenta-specific 8 (PLAC8), a key upstream molecule in the
brown adipogenic regulatory network, functions by associ-
ating with C/ebpb and binding to its promoter to induce
transcription (88). In vivo genetic deletion of Plac8 results
in the loss of expression of several brown fat-specific
components such as Prdm16 and Pgc1a. However, general
adipocyte differentiation factors such as PPARg and AP2
are not downregulated, indicating the importance of PLAC8
in recruiting BAT during thermogenic challenges. Conse-
quently, in vivo genetic inactivation of Plac8 leads to errors
in BAT differentiation and thermogenic programs, causing
cold intolerance and late onset obesity (88). However, the
upstream signaling activators of Plac8 induction and those
that promote PLAC8 binding to C/EBPb are as yet
uncharacterized and merit further investigation.
CCAAT/enhancer binding protein beta and
CCAAT/enhancer binding protein delta
PPARg and C/EBPs, the key molecular players of adipogen-
esis, vary in their molecular function in brown versus white
fat programs. In response to pro-adipogenic stimuli,
C/EBPb and C/EBPd transition from a repressive complex,
involving the nuclear co-repressors NCoR1 and SMRT
(89), into an active one. This in turn allows these TFs to
induce expression of PPARg and C/EBPa in cooperation
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© 2017 The Authors. Obesity Reviews published by John Wiley & Sons Ltd on behalf of World Obesity Obesity Reviews 18 (Suppl. 1), 65–81, February 2017
with the epithelial–mesenchymal transition TF ZEB1 (90),
which drives terminal fat cell differentiation. C/EBPb is
important for adipogenic differentiation in immortalized
adipocytes with slightly inconspicuous effect in mouse
embryonic fibroblasts (MEFs). While it has been demon-
strated that C/EBPb-deficient mice have reduced adiposity,
this might be attributed to impairment in lipogenic and
not adipogenic programs (54,91). It is quite likely that
C/EBPd may take over for C/EBPb in a knock out model,
as a double knockout mouse model for C/ebpb and C/ebpd
shows a further decline in adipose tissue mass (91).
Moreover, C/EBPb has been shown to work in collabora-
tion with PPARg to induce the expression of C/ebpa, as
PPARg is required to release the inhibitory chromatin
remodeler HDAC1 from the C/ebpa promoter (92). Thus,
C/EBP -b and -d work synergistically with other members
of the core differentiation circuit to execute downstream
gene regulatory programs.
Core differentiation circuit
Peroxisome proliferator-activated receptor gamma
The ligand-dependent nuclear receptor PPARg expressed
primarily in adipocytes is induced during adipogenesis and
is central to the adipogenic regulatory network. It has two
different isoforms, PPARg1 and PPARg2, of which PPARg2
is exclusively present in the adipose tissue in contrast to
PPARg1, which is ubiquitously expressed. PPARg functions
as a regulator in adipogenic programs common to both
white and brown fat differentiation, and no other factor
has so far been found that can promote adipogenesis in
the absence of PPARg. All pro-adipogenic transcriptional
regulators such as C/EBPs and some KLFs such as KLF5,
KLF15 converge on one of the two Pparg promoters while
anti-adipogenic transcriptional regulators such as the GATA
factors function by repressing Pparg expression (93–95).
Additionally, key adipogenic signaling pathways also
converge on Pparg expression and activity. Upon activation
by ligands, PPARg forms a heterodimer with RXR and
binds to a Ppar response element (PPRE) in cooperative
fashion (96,97), enabling it to control the expression of a
specific subset of PPRE-containing genes such as Ap2,
Fabp4 and Lpl in white adipocytes (98). Studies showed
that stimulation of white adipocytes in vitro or in vivo by
strong PPARg agonists such as rosiglitazone leads to
‘browning’ of the white cells (99). The latter triggers an
upregulation of mitochondrial genes such as Ucp1, Cox7a1
and Cox8b, subsequently causing an increase in mitochon-
drial mass, enhanced oxygen consumption and lipid
oxidation (100,101). This browning effect is characterized
by a suppression of adipokine production such as Resistin,
Alpha1-acidoglycoprotein and Haptoglobin (102–104).
The phenotypic outcome of supplementing white adipocytes
already known to express Pparg and its endogenous ligands
with additional PPARg agonists suggests that brown
adipocytes produce a distinct repertoire of PPARg ligands
that differ in activity from those produced in white adipo-
cytes (105). It is likely that this regulatory mechanism is
then executed via the actions of PRDM16/PGC1a and
PRDM16/CtBP complexes as they are known to mediate
brown versus white programs.
CCAAT/enhancer binding protein alpha
C/EBPa plays a crucial role in differentiated adipocytes and
works in concert with PPARg to constitute the core differen-
tiation circuit. The molecular function of C/EBPa is central
to the acquisition of insulin sensitivity as opposed to accu-
mulation of lipids or expression of adipocyte genes (106).
Nuclear Factor IA
The Nuclear Factor I (NFI) family of TFs including NFIA,
NFIB, NFIC and NFIX are widely expressed, with each TF
regulating a distinct set of target genes as evidenced by
different phenotypes yielded by mouse knockout models
(107). Previously, both NFIA and NFIB have been identified
as positive regulators of white adipocyte differentiation via
in vitro cell culture studies in the 3T3L1 cell line (108). Using
an integrative genomics approach, we discovered that NFIA
is also involved in the brown adipogenesis gene regulatory
network (109). Notably, we observed that Nfia is differen-
tially expressed during brown fat cell differentiation and
has a strong positive correlation withUcp1 expression levels
in themouse genetic reference panel (BXD) (110) and human
clonal BAT cell lines (111). Further, genome-wide localiza-
tion analyses based on ChIP-seq revealed that, while NFIA
does not directly bind toUcp1, it does, however, bind to gen-
eral adipogenic marker genes such as Zfp423, core
adipogenic regulators such as Pparg and Rxrg, early brown
specific TFs such as Ebf2 and finally drivers of the thermo-
genic module such as Ppara and Pgc1a. A follow-up on the
mechanistic details of NFIA action in brown versus white
is necessary, especially to delineate its mode of regulatory ac-
tion in these tissue types.
Apart from the core members of this differentiation circuit,
additional adipogenic regulators include positive regulators
such as ZEB1 (90), ASLX2 (112), Kruppel like factors
(KLF)-5 (93), -15 (113) and 6 (114), STAT5a (115,116), while
negative regulators include GATA transcription factors
(94,95), ASLX1 (112), KLF-2 (117). These transcriptional de-
tails have been reviewed extensively elsewhere (54,105).
Thermogenic circuit
Peroxisome proliferator-activated receptor alpha
The peroxisome proliferator-activated receptor alpha
(PPARa), a protein from the nuclear receptor family
comprising PPARg/d/b, is a fatty acid-activated TF that
executes transcriptional regulation of genes involved in
74 Systems perspective on brown adipogenesis R. N. Pradhan et al. obesity reviews
© 2017 The Authors. Obesity Reviews published by John Wiley & Sons Ltd on behalf of World ObesityObesity Reviews 18 (Suppl. 1), 65–81, February 2017
cellular metabolism (118). It is particularly detected in
tissues such as brown fat, liver or heart, known to have high
rates of fatty acid oxidation and peroxisomal metabolism.
High expression of Ppara distinguishes brown from white
fat and is related to the lipid oxidation capacity of brown
fat. It was shown that PPARa activators stimulate Ucp1
gene expression both in brown adipocytes and mature
BAT, acting through a PPRE element situated in the
upstream enhancer of the Ucp1 gene that is also responsible
for PPARg-dependent regulation (119). PPARa interacts
with CBP and PGC1a, forming a tight regulatory complex
to activate Ucp1 gene expression. An interesting regulatory
mechanism exists between the two PPARs, PPARa and
PPARg, during brown adipogenesis. While it was demon-
strated that PPARa and PPARg bind and activate Ucp1 gene
transcription through the same Ucp1-PPRE element, the
predominant molecular function of any particular subtype
depends on the relative amount of each subtype. For exam-
ple, crosstalk with other signaling pathways such as regula-
tion of PPAR transcriptional activity by MAPK-dependent
phosphorylation enhances PPARa (120) but decreases
PPARg activity (121), as well as ligand availability and
interaction with co-regulators such as PGC1a. The interac-
tion of PGC1a with PPARa is ligand dependent, whereas
the one with PPARg is not (122). Therefore, these and
possibly other uncharacterized events may determine which
PPAR subtype activates Ucp1 transcription in response to
brown adipocyte-inducing conditions. In other words, it
could be PPARg in association with differentiation-
dependent events, or PPARa in conjuction with increased
lipid catabolism in active BAT, highlighting the importance
of understanding this regulatory mechanism. Further, it
was observed that acute administration of the PPARa ligand
Wy 14,643 upregulates Ucp1 mRNA expression in those
physiological situations in which endogenous PPARa
ligands are expected to be low. This is in agreement with
previous findings demonstrating that PPARa sensitivity
in vivo depends upon the status of lipid metabolism (123).
Carbohydrate response element binding protein
Yet another interesting mechanism is the differential regula-
tion of PPARa and carbohydrate response element binding
protein (ChREBP), a TF that is responsive to glucose signal-
ing and is more highly expressed in brown compared to
white fat tissue, influencing lipid storage and lipolysis in
brown adipocytes. It was demonstrated that ChREBP and
PPARa regulate each other via an inhibitory feedback mech-
anism that is activated during conditions of high and low
glucose, respectively (124). As such, ChREBP and PPARa
coordinately establish a feedback loop between lipogenesis
and lipolysis in brown adipocytes. The molecular mecha-
nism underlying this crosstalk remains largely unexplored
and may serve as an avenue for further research to develop
novel therapeutics.
Peroxisome proliferator-activated receptor gamma,
coactivator 1 alpha
Given that PPARg alone is insufficient to induce browning,
extensive investigation into other putative regulators led to
the identification of PGC1a. The involvement of PGC1a
was first demonstrated in the thermogenic circuit when a
dramatic increase in Pgc1a expression was observed in mice
exposed to cold in both skeletal and brown fat (122). PGC1a
is also triggered in brown fat cell lines upon treatment with
the beta-adrenergic receptor agonist isoproterenol (122). It
interacts with multiple nuclear hormone receptors that bind
to the Ucp1 gene enhancer in either a ligand-dependent or -
independent manner as in the case of Retinoic Acid Receptor
(RAR) and Thyroid Receptor (TR) or PPARg, respectively.
PGC1a not only boosts the efficiency of transcription but
also plays a key role in specifying the genes that are targeted
by its partner TFs. This is illustrated by overexpression of
PGC1a in white fat cells leading to the induction of Ucp1
through the PPARg binding sites but a failure to express
the PPARg target gene Ap2. As PGC1a is a co-activator
and is dependent on the binding of particular TFs to imple-
ment different gene expression programs, repression of bind-
ing events could affect different biological responses. Thus,
targeting singular binding events between PGC1a and par-
ticular TFs might offer new therapeutic opportunities.
However, while PGC1a is a critical regulator of adaptive
thermogenesis, it is not the master regulator of brown differ-
entiation. This is evidenced by the fact that reduction in
PGC1a levels during brown fat cell differentiation has no
significant impact on brown adipogenesis. However, it has
a strong impact on the induction of thermogenic genes by
cAMP (105). Apart from its molecular involvement in regu-
lating thermogenesis, it also aids in inducing angiogenesis
via the co-activation of the orphan nuclear receptor ERRA
on the Vegf promoter. PGC1a was stimulated by an inade-
quacy in nutrients as well as oxygen leading to increased
Vegf expression and subsequently angiogenesis in BAT and
skeletal muscle in vivo (125). Thus, the transcriptional func-
tions of PGC1a are key to the development and thermogenic
activity of brown adipocytes.
Forkhead box C2
Forkhead box protein C2 (FOXC2), a member of the
Forkhead box family of TFs, regulates different aspects of
adipocyte metabolism by activating PPARg and C/EBPa as
well as by enhancing cAMP-mediated PKA signaling
(126). Most importantly, FOXC2 responds strongly to high
caloric load via strong induction of cAMP signaling as
demonstrated by high fat feeding experiments in which
FOXC2-overexpressing mice showed reduced weight gain
in response to the amount of food consumed. This catego-
rizes FOXC2 as a putative therapeutic target based on its
molecular function as a metabolic regulator and a factor
that can induce adaptive thermogenesis (126). Additionally,
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enhanced expression of Foxc2 has also been implicated in
mitochondrial biogenesis via trans-activation of the nuclear
encoded mitochondrial transcription factor A as well as
induction of mitochondrial fusion via activation ofMitofusin
1 and 2, and Optic atrophy 1 homolog (127). This correla-
tion was observed in humans, making FOXC2 an attractive
target for therapy. Foxc2 expression was also shown to in-
crease in response to high caloric feeding, whilst repressed
by cold (127). This suggests that FOXC2 has a distinct role
in regulating mitochondrial function from that observed in
cold-adapted thermogenesis, known as metabolo-regulatory
thermogenesis. This is different from thermo-regulatory ther-
mogenesis, which is categorically induced by cold and is de-
pendent on expression of Pgc1a and Ucp1 (8).
In addition to the key factors described above, new fac-
tors have recently been implicated in early brown adipogen-
esis. These include the Kruppel like factor 11 that binds to
PPARg and activates brown fat genes in rosiglitazone-
treated human adipocytes (128) as well as the EWS/YBX1/
BMP7 axis, in which the RNA-binding protein EWS along
with its partner YBX1 transcriptionally activates Bmp7 to
induce browning (129). Additionally, new factors impli-
cated in the thermogenic program are Zinc-finger protein
516 (ZFP516) that is involved in the activation of Ucp1
gene expression by interacting with PRDM16 (130) and in-
terferon regulatory factor-4 (IRF4), an important TF part-
ner of PGC1a that both induces and interacts with PGC1a
to activate thermogenic genes (131). A new regulatory layer
comprising small non-coding RNAs, miRNAs such as miR-
193b-365, miR-133, miR-196a, miR-155, miR-27, miR-
378, miR-34a along with BAT-specific long-noncoding
RNAs such as lnc-BATE1 and Blnc1 is also known to pro-
mote brown and/or beige adipocyte differentiation and
physiological function (132).
Anti-adipogenic regulators affecting the PGC1a–
UCP1 axis
Given the central function of PGC1a and UCP1 in the
thermogenic program, their expression and activity are
tightly regulated by a multitude of factors that serve as
negative regulators. This mode of negative regulation most
likely functions to restrain thermogenesis, whose prolonged
activation may lead to adverse conditions such as hyperther-
mia, which in turn has the potential to cause organ failure
and death (133).
Nuclear receptor interacting protein 140
Nuclear receptor (NR) interaction protein 140 (Rip140) is a
ligand-dependent transcriptional repressor of nuclear
receptors including estrogen receptor and PPARs and also
functions as a transcriptional co-repressor that shares a
number of downstream targets with PGC1a and inhibits
PGC1a’s transcriptional activity by binding to it directly
(134). Along with suppressing PGC1a target genes,
Rip140 also represses Ucp1 expression by recruiting inhibi-
tory histone modifying and DNA methylation enzymes to
the promoter of Ucp1 (135). Lack of Rip140 increases
Ucp1 expression by de-repression of PPARa, PPARg and
PGC1a. Studies suggest that, given Rip140’s high expres-
sion in WAT compared to BAT, it functions to suppress the
brown phenotype. This is evidenced by significant enhance-
ment of brown-related genes upon knockdown of Rip140 in
white fat cells (136). Further, observations from in vivo
studies demonstrated that Rip140 null mice exhibit
expenditure rather than storage of the consumed fat (137).
However, in-depth investigation into the molecular mecha-
nisms underlying Rip140-mediated ‘browning’ suppression
is pending.
Liver X receptor alpha
The Liver X receptor alpha (LXRa) does not directly
interfere with PGC1a’s transcriptional activity or binding,
rather, when ligand-activated, this TF interferes with the
induction of Ucp1 expression by displacing PPARg from
the Ucp1 enhancer and by drafting RIP140 as a corepressor
to its binding site (133). It has also been demonstrated that
mice lacking LXRa show increased Ucp1 expression in both
BAT and WAT with no significant change in the expression
of Pgc1a, thus manifesting a lean phenotype (133,138).
Retinoblastoma protein
pRb acts as a molecular toggle between the white and
brown adipocyte differentiation programs (139) by direct
binding to the Pgc1a promoter leading to transcriptional
repression (140). Additionally, pRb functions as a PPARg
co-repressor, thereby suppressing its transcriptional
activity (141).
Twist basic helix–loop-helix TF 1
Twist basic helix–loop-helix TF 1 (TWIST1) functions as
an antagonist of brown fat-mediated thermogenesis by
binding directly to PGC1a and suppressing its transcrip-
tional activity. This is executed by Twist1-mediated
recruitment of the histone deacetylase HDAC5 to the
promoters of PGC1a target genes, causing transcriptional
repression (142).
Other key anti-adipogenic factors suppressing the PGC1a
and UCP1 axis include unliganded Vitamin D receptor that
directly suppresses Ucp1 expression via binding to a
Vitamin D receptor element in the proximal region of the
Ucp1 promoter (133), steroid receptor co-activators such
as SRC2 and SRC3 that repress the transcriptional activity
of PGC1a, TRPV4 (a transient receptor potential cation
channel 4) that represses PGC1a via the ERK1/2 protein
kinases (143) and SHP (orphan nuclear receptor) that in-
hibits the ERR-g mediated promoter transactivation of
PGC1a (133).
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Outlook
While the white adipocyte differentiation network is well
characterized, the brown adipogenic signaling and gene reg-
ulatory network remains rather sparse, warranting further
investigation to annotate missing nodes and interactions.
The latter include additional regulators that are capable of
inducing browning in concert with key molecular players,
thereby providing alternative points of safe therapeutic
intervention. Most notably, through a comprehensive
literature-based reconstruction of the brown signaling and
gene regulatory network, we illustrate the requirement to
focus on delineating implicated signaling pathways and on
how they converge on the transcriptional components. This
will enable a more thorough understanding of key molecu-
lar events and guide better drug discovery efforts. An
additional focus should be on elucidating mechanisms that
govern the white to brown switch, aiding in the develop-
ment of drugs that can safely and specifically mediate
browning.
Recent studies have also elucidated alternative modes of
thermogenesis that function without the need for UCP1
activation, wherein beige and white adipocytes can directly
respond to cool temperature (27–33°C) and activate a ther-
mogenic program in a cell-autonomous manner. This partic-
ular type of thermogenic program was determined to be
independent of the canonical cAMP/protein kinase/CREB
pathway downstream of beta-adrenergic signaling (144).
Furthermore, in a study conducted on human subjects, it
was observed that elevated thermogenesis upon cold expo-
sure is not inhibited by the chemical blockade of beta-
adrenergic signaling alone (145). This suggests the existence
of alternative pathways for induction of a thermogenic pro-
gram through a cell-autonomous effect of temperature on
certain fat depots. Recently, a futile cycle of creatine metab-
olism has been identified as an alternative pathway for
energy expenditure and thermal homeostasis (146). The
implicated proteins Creatine Kinase Mitochondrial 1 and
2 (CKMT1 and CKMT2) were enriched in human BAT,
raising the possibility of exploiting this pathway in manipu-
lating energy consumption in patients with metabolic
diseases, particularly via dietary supplementation and/or
administration of novel drugs.
One of the main challenges in the field of translational
research is the design of safe therapeutic interventions.
Several treatment options targeting BAT are being explored,
but more often than not, they suffer from potential systemic
side effects. We believe that a systems perspective summariz-
ing various input stimuli, downstream signaling and
transcriptional components will provide a strong frame-
work to aid in the development of targeted drug design. Fur-
thermore, the field’s focus should not only be on identifying
specific druggable pathways but also strategies for drug de-
livery such as the development of controllable microenvi-
ronments, scaffolds, biomaterials for transplantation of
energy expending cells as well as focused pharmacological
intervention to stimulate the activity of resident progenitor
cells in situ by triggering endogenous brown adipogenesis.
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